Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun;179(6):1098-1106.
doi: 10.1002/ajmg.a.61112. Epub 2019 Mar 25.

From process to progress-2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis

Affiliations

From process to progress-2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis

Rosalie E Ferner et al. Am J Med Genet A. 2019 Jun.

Abstract

The neurofibromatoses are inherited, tumor suppressor disorders that are characterized by multiple, benign peripheral nerve sheath tumors and other nervous system tumors. Each disease is associated with a distinct genetic mutation and with a different pathogenesis and clinical course. Neurofibromatosis 1 (NF1) is common and epitomized by multiple neurofibromas with widespread complications. NF2 and schwannomatosis are rare diseases that are typified by multiple schwannomas that are particularly painful in people with schwannomatosis. Since 1985, the Children's Tumor Foundation (formerly the National Neurofibromatosis Foundation) has hosted an international Neurofibromatosis Conference, bringing together international participants who are focused on NF research and clinical care. The 2017 Conference, held in Washington, DC, was among the largest gatherings of NF researchers to date and included presentations from clinicians and basic scientists, highlighting new data regarding the molecular and cellular mechanisms underlying each of these diseases as well as results from clinical studies and clinical trials. This article summarizes the findings presented at the meeting and represents the current state-of-the art for NF research.

Keywords: neurofibromatosis 1; neurofibromatosis 2; schwannomatosis.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

The authors declare they have no conflicts of interest

References

    1. Alves F, Vogel W, Mossie K, Millauer B, Hofler H, & Ullrich A (1995). Distinct structural characteristics of discoidin I subfamily receptor tyrosine kinases and complementary expression in human cancer. Oncogene, 10(3), 609–618. - PubMed
    1. Boetto J, Apra C, Bielle F, Peyre M, & Kalamarides M (2018). Selective vulnerability of the primitive meningeal layer to prenatal Smo activation for skull base meningothelial meningioma formation. Oncogene. 10.1038/s41388-018-0328-7 - DOI - PubMed
    1. Cooper J, Xu Q, Zhou L, Pavlovic M, Ojeda V, Moulick K, … Giancotti FG (2017). Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis. Mol Cancer Ther, 16(8), 1693–1704. 10.1158/1535-7163.Mct-16-0821 - DOI - PMC - PubMed
    1. de Blank PMK, Fisher MJ, Liu GT, Gutmann DH, Listernick R, Ferner RE, & Avery RA (2017). Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision. J Neuroophthalmol, 37 Suppl 1, S23–s32. 10.1097/wno.0000000000000550 - DOI - PMC - PubMed
    1. Evans DG, Bowers NL, Tobi S, Hartley C, Wallace AJ, King AT, … Smith MJ (2018). Schwannomatosis: a genetic and epidemiological study. J Neurol Neurosurg Psychiatry. 10.1136/jnnp-2018-318538 - DOI - PubMed

Publication types

MeSH terms

Supplementary concepts